Sensorion Completes Second Cohort Enrollment in OTOF Gene Therapy Clinical Trial
SENS-501 is a gene therapy candidate being developed to treat a form of congenital deafness linked to mutations in the OTOF (otoferlin) gene.
Tag: clinical trials
All
Latest
All
Latest
Sound Pharma Gets Positive Results from Meniere’s Disease Drug Clinical Trial
Sound Pharmaceuticals' Phase 3 trial of an anti-inflammatory drug for Meniere’s disease showed significant improvements in hearing loss.
All
Latest
France Approves Gene Therapy Clinical Trial to Treat Hearing Loss in Children
The clinical trial will test a gene therapy drug to treat children with a form of hereditary deafness caused by mutations in the OTOF gene.
Frequency Therapeutics Reports Disappointing Trial Results for Hearing Restoration Drug
Frequency Therapeutics announced topline results from its recent study, showing that four weekly injections of its FX-322 treatment therapy in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo. FX-322, the company’s lead product candidate, made news last month when a study published in ‘Otology & Neurotology’ indicated the “first known linkage of pharmacokinetics and pharmacodynamics for a potential hearing restoration therapy.”
Read More
Frequency Therapeutics Publishes FX-322 Phase 1/2 Results
The data show hearing improvements in adults with acquired sensorineural hearing loss (SNHL) and the “first known linkage of pharmacokinetics and pharmacodynamics for a potential hearing restoration therapy,” according to Frequency.
Read More
Auris Medical Completes Enrollment in Phase 2 Study for Vertigo Drug
The Company expects to release interim results from TRAVERS and commence Part B of the trial in the coming weeks.
Read More
Otonomy Announces Positive Top-Line Results from Tinnitus Drug Trial
The trial reportedly achieved its objectives by demonstrating a positive clinical signal for OTO-313 based on a TFI responder analysis, with a favorable safety profile, according to the company.
Read More
Frequency Therapeutics Announces Clinical Data from Auditory Drug
FX-322 is Frequency’s lead product candidate, designed to regenerate auditory sensory hair cells in the cochlea and improve hearing in patients with sensorineural hearing loss (SNHL).
Read More
Sensorion Announces Updated Timelines for Phase 2 Study of Hearing Loss Drug
Sensorion (FR0012596468 – ALSEN) a clinical-stage biotech company which specializes in the...
Read More
Akouos Announces Gene Therapy to Treat Genetic Hearing Loss
AK-OTOF is intended to treat individuals with sensorineural hearing loss due to mutations in the OTOF gene, who typically have severe hearing loss in both ears from birth, by promoting the expression of normal, functional otoferlin protein in affected cells of the cochlea.
Read More
Sensorion Receives IND Clearance from FDA on Hearing Loss Drug
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Otonomy Initiates Clinical Trial for Tinnitus Drug
The randomized, double-blind, placebo-controlled Phase 1/2 study will include an initial safety cohort followed by an exploratory efficacy study that will enroll approximately 50 patients with subjective tinnitus.
Read More
Audion Therapeutics and Regain Consortium Report Positive Phase I Results from Drug to Treat SNHL
LY3056480 mediated Notch inhibition is aimed at regeneration of inner ear sensory hair cells that are lost with advancing age.
Read More
Otonomy Presents Data on OTO-413 Therapy for Hearing Loss
These preclinical data, demonstrating the potential of intratympanic BDNF to repair cochlear synaptopathy—an underlying cause of hearing loss including speech-in-noise hearing difficulty—are being presented as part of the Society for Neuroscience (SfN) Annual Meeting in San Diego, November 3-7, 2018.
Read More
NF2 Trial: An Interview with Rick Friedman, MD, PhD
Hearing Review interviewed Rick Friedman, MD, PhD, about NF2 and an NF2 clinical that is underway in Los Angeles and at 12 other sites in the US. The trial uses the chemotherapy drug Avastin (bevacizumab) as a potential therapy for shrinking NF2 tumors, or stemming their growth.
Read More
Drug Trial Results Offer Hope for Ménière’s, Tinnitus Patients
Otonomy, which develops and commercializes therapeutics for ear diseases and disorders, reported that its development of investigational drugs to help patients with Ménière’s disease and tinnitus, have had positive results in clinical trials.
Read More